Medical device manufacturers Boston Scientific, Abbott Laboratories and Medtronic have filed paperwork to remove their most advanced drug-eluting coronary stents from the Indian market, arguing that price caps force them to lose money. Indian authorities so far have not allowed the companies to withdraw their products, but the government has offered to consider creating a higher-paying stent tier if the companies can provide proof that the newer models offer superior performance to justify the higher prices. "I know from working with all of our other members in India, they are equally concerned because of the severity of what happened with stents," said AdvaMed's Vice President of Global Strategy Abby Pratt.
India, manufacturers in standoff over coronary stent prices
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.